Results 91 to 100 of about 5,941 (192)

Comparison of clinical and pharmacodynamic features of proton pump inhibitors efficacy in gastroesophageal reflux disease

open access: yesРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015
The aim of review. To present literature data on clinical presentation, pharmacodynamic and economic efficiency of standard dozes of proton pump inhibitors (PPI) for gastroesophageal reflux disease (GERD).Summary.
O. A. Storonova, A. S. Trukhmanov
doaj  

Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial

open access: yes, 2010
Background & Aims: There is controversy about the efficacy of treating patients with laryngopharyngeal reflux (LPR) using proton pump inhibitors (PPIs). We assessed the effects of high doses of the PPI rabeprazole in patients with LPR.
Wei, WI   +7 more
core   +1 more source

Assessment of Food Effect and pH‐Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects

open access: yesClinical and Translational Science
This two‐sequence, three‐period study (NCT04645940) was designed to evaluate the effect of food and concomitant rabeprazole, a proton pump inhibitor, on the pharmacokinetics (PK) and safety of fruquintinib and its metabolite M11 after a single oral dose ...
Martha Gonzalez   +5 more
doaj   +1 more source

Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers

open access: yes, 2018
<b><i>Background and Aims:</i></b> Endoscopic submucosal dissection (ESD) is a well-established minimally invasive treatment for early gastric cancer. To heal ESD-induced ulcers, we commonly prescribe proton pump inhibitors (PPIs).
Yusuke Muramatsu   +8 more
core   +1 more source

The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury

open access: yes, 2018
BACKGROUND:Simultaneous use of proton pump inhibitors (PPIs) has been shown to increase the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced small bowel injury.
貫, 陽一郎   +2 more
core  

A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations [PDF]

open access: yes, 2008
Clozapine is a drug of choice for treatment of refractory schizophrenia, which is primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main metabolite.
Naghmeh, Jabarizadekivi
core  

Is Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years? [PDF]

open access: yes, 2015
Objective: The objective of the selective EBM review is to determine whether or not Rabeprazole is a safe treatment for GERD in children less than sixteen years old. Study Design: Review of three randomized controlled studies.
Applegarth, Sarah
core  

SIMULTANEOUS ESTIMATION OF FAMOTIDINE AND RABEPRAZOLE SODIUM: METHOD DEVELOPMENT AND VALIDATION BY UV-SPECTROPHOTOMETRIC METHOD [PDF]

open access: yes, 2015
Objectives: Study aimed for the simultaneous estimation of Famotidine and Rabeprazole sodium at 263 nm, λmax of Famotidine and 284 nm, λmax of Rabeprazole sodium.Methods: Method development and validation were done by UV spectrophotometric method ...
Dsouza, Lenson Paul, Koland, Marina
core  

Time-Dependent Amplified Pharmacokinetic and Pharmacodynamic Responses of Rabeprazole in Cytochrome P4502c19 Poor Metabolizers

open access: yes, 2008
Objectives: To determine the pharmacokinetic (PK) and pharmacodynamic (PD) rationale for the optimal regimen of rabeprazole in the treatment of H. pylori infection in CYP2C 19 PMs and EMs.
LIN, CHUN-JUNG;YANG, JYH-CHIN;UANG, YOW-SHIEN;WANG, TEH-HONG;CHERN, HERNG-DER   +1 more
core  

DEVELOPMENT AND OPTIMIZATION OF RABEPRAZOLE CHRONO-MODULATED DRUG DELIVERY SYSTEMS

open access: yes
Objective: Development and optimization of chrono-modulated pulsatile drug delivery systems (CPDDS) loaded with Rabeprazole for treating nocturnal acid breakthrough in ulcer patients was set as the major objective of this work.
KURAPATI, PHANEENDRA   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy